Cargando…
Shewanella putrefaciens, a rare human pathogen: A review from a clinical perspective
Shewanella putrefaciens is a gramnegative, facultatively anaerobic, rod shaped bacterium. It belongs to the class of the Gammaproteobacteria and was first described in 1931. S. putrefaciens is part of the marine microflora and especially present in moderate and warm climates. The bacterium is a rare...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9933709/ https://www.ncbi.nlm.nih.gov/pubmed/36817694 http://dx.doi.org/10.3389/fcimb.2022.1033639 |
_version_ | 1784889728091291648 |
---|---|
author | Müller, Stephanie von Bonin, Simone Schneider, Ralph Krüger, Martin Quick, Susanne Schröttner, Percy |
author_facet | Müller, Stephanie von Bonin, Simone Schneider, Ralph Krüger, Martin Quick, Susanne Schröttner, Percy |
author_sort | Müller, Stephanie |
collection | PubMed |
description | Shewanella putrefaciens is a gramnegative, facultatively anaerobic, rod shaped bacterium. It belongs to the class of the Gammaproteobacteria and was first described in 1931. S. putrefaciens is part of the marine microflora and especially present in moderate and warm climates. The bacterium is a rare oppurtonistic human pathogen associated mainly with intra-abdominal as well as skin and soft tissue infections. However, it has also been reported in association with more severe diseases such as pneumonia, intracerebral and ocular infections and endocarditis. In these cases the clinical courses are often associated with underlying, predisposing diseases and risk factors. For successful treatment of S. putrefaciens, a combination of appropriate local therapy, e.g. surgical treatment or drainage, and antibiotic therapy should be performed. Since multiple resistances to antibiotics are described, the results of the antimicrobial susceptibility testing must be considered for effective therapy as well. Furthermore, a main challenge in clinical practice is the accurate microbiological identification, and especially the correct differentiation between S. putrefaciens and S. algae. Under certain circumstances, Shewanella-infections can have severe, sometimes even fatal consequences. Therefore, we decided to present the current state of knowledge as well as further aspects with regard to future diagnostics, therapy and research. |
format | Online Article Text |
id | pubmed-9933709 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-99337092023-02-17 Shewanella putrefaciens, a rare human pathogen: A review from a clinical perspective Müller, Stephanie von Bonin, Simone Schneider, Ralph Krüger, Martin Quick, Susanne Schröttner, Percy Front Cell Infect Microbiol Cellular and Infection Microbiology Shewanella putrefaciens is a gramnegative, facultatively anaerobic, rod shaped bacterium. It belongs to the class of the Gammaproteobacteria and was first described in 1931. S. putrefaciens is part of the marine microflora and especially present in moderate and warm climates. The bacterium is a rare oppurtonistic human pathogen associated mainly with intra-abdominal as well as skin and soft tissue infections. However, it has also been reported in association with more severe diseases such as pneumonia, intracerebral and ocular infections and endocarditis. In these cases the clinical courses are often associated with underlying, predisposing diseases and risk factors. For successful treatment of S. putrefaciens, a combination of appropriate local therapy, e.g. surgical treatment or drainage, and antibiotic therapy should be performed. Since multiple resistances to antibiotics are described, the results of the antimicrobial susceptibility testing must be considered for effective therapy as well. Furthermore, a main challenge in clinical practice is the accurate microbiological identification, and especially the correct differentiation between S. putrefaciens and S. algae. Under certain circumstances, Shewanella-infections can have severe, sometimes even fatal consequences. Therefore, we decided to present the current state of knowledge as well as further aspects with regard to future diagnostics, therapy and research. Frontiers Media S.A. 2023-02-02 /pmc/articles/PMC9933709/ /pubmed/36817694 http://dx.doi.org/10.3389/fcimb.2022.1033639 Text en Copyright © 2023 Müller, von Bonin, Schneider, Krüger, Quick and Schröttner https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cellular and Infection Microbiology Müller, Stephanie von Bonin, Simone Schneider, Ralph Krüger, Martin Quick, Susanne Schröttner, Percy Shewanella putrefaciens, a rare human pathogen: A review from a clinical perspective |
title |
Shewanella putrefaciens, a rare human pathogen: A review from a clinical perspective |
title_full |
Shewanella putrefaciens, a rare human pathogen: A review from a clinical perspective |
title_fullStr |
Shewanella putrefaciens, a rare human pathogen: A review from a clinical perspective |
title_full_unstemmed |
Shewanella putrefaciens, a rare human pathogen: A review from a clinical perspective |
title_short |
Shewanella putrefaciens, a rare human pathogen: A review from a clinical perspective |
title_sort | shewanella putrefaciens, a rare human pathogen: a review from a clinical perspective |
topic | Cellular and Infection Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9933709/ https://www.ncbi.nlm.nih.gov/pubmed/36817694 http://dx.doi.org/10.3389/fcimb.2022.1033639 |
work_keys_str_mv | AT mullerstephanie shewanellaputrefaciensararehumanpathogenareviewfromaclinicalperspective AT vonboninsimone shewanellaputrefaciensararehumanpathogenareviewfromaclinicalperspective AT schneiderralph shewanellaputrefaciensararehumanpathogenareviewfromaclinicalperspective AT krugermartin shewanellaputrefaciensararehumanpathogenareviewfromaclinicalperspective AT quicksusanne shewanellaputrefaciensararehumanpathogenareviewfromaclinicalperspective AT schrottnerpercy shewanellaputrefaciensararehumanpathogenareviewfromaclinicalperspective |